Annexin Pharmaceuticals AB (publ) Stock Nasdaq Stockholm
Equities
ANNX BTA
SE0013748894
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- SEK | -.--% | -3.17% | -.--% |
Sales 2024 * | - | Sales 2025 * | 39.6M 3.75M 5.16M | Capitalization | 157M 14.85M 20.42M |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.93M -6.78M | Net income 2025 * | -16M -1.52M -2.09M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.4M 1.74M 2.4M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.96 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.62% |
Managers | Title | Age | Since |
---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 13-12-31 |
Chief Executive Officer | 63 | 17-12-31 | |
Director of Finance/CFO | 53 | 23-04-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 20-12-31 |
Mårten Österlund
BRD | Director/Board Member | 67 | 20-12-31 |
Chief Executive Officer | 63 | 17-12-31 |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+4.31% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-16.57% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ANNX Stock
- ANNX BTA Stock